Literature DB >> 20160713

Impact of functional gastrointestinal disorders on survival in the community.

Joseph Y Chang1, G Richard Locke, Meredythe A McNally, Smita L Halder, Cathy D Schleck, Alan R Zinsmeister, Nicholas J Talley.   

Abstract

OBJECTIVES: Functional gastrointestinal disorders (FGIDs) comprise a constellation of symptoms that have no identifiable structural or biochemical abnormality. In view of the lack of data from large-scale population-based studies evaluating the effects of these disorders on survival, we aimed to examine whether FGIDs are associated with impaired survival.
METHODS: Between 1988 and 1993, valid self-report questionnaires that recorded gastrointestinal symptoms required for the diagnosis of irritable bowel syndrome (IBS), chronic constipation, chronic diarrhea, dyspepsia, and abdominal pain were mailed to randomly selected cohorts of Olmsted County, Minnesota residents. Minnesota administrative death records were used to identify which of the survey respondents had died over the follow-up period (through April 2008). The association between survival and each FGID was assessed using proportional hazards regression models with univariate and adjusted hazard ratios (HRs, 95% confidence intervals (CIs)), adjusting for age at time of survey, gender, smoking, alcohol, marital status, and Charlson Comorbidity Index (CCI).
RESULTS: Of the 5,262 randomly selected eligible subjects who received a questionnaire, a total of 4,176 responded to the surveys (overall response rate 79%). From these respondents, 243 subjects were excluded because of lack of research authorization (or were registered solely at a different medical institution in Olmsted County, MN), resulting in 3,933 eligible subjects for analysis (eligible response rate 75%); 10% reported symptoms of IBS; 16% chronic constipation; 18% chronic diarrhea; 2% dyspepsia; and 15% abdominal pain. At baseline, the mean (s.d.) age was 54 (18) years, and 52% were female. No association with overall survival was detected for IBS (HR=1.06 (95% CI: 0.86-1.32)), chronic diarrhea (HR=1.03 (95% CI: 0.90-1.19)), abdominal pain (HR=1.09 (95% CI: 0.92-1.30)), or dyspepsia (HR=1.08 (95% CI: 0.58-2.02)). Reporting symptoms of chronic constipation was associated with poorer survival (HR=1.23 (95% CI: 1.07-1.42)). This association remained significant after adjusting for the CCI (HR=1.19 (95% CI: 1.03-1.37)).
CONCLUSIONS: In this large population-based cohort study with over 30,000 person-years of follow-up, no significant association was observed between survival and IBS, chronic diarrhea, dyspepsia, or abdominal pain. Furthermore, no association was found between increasing burden of FGIDs and survival. However, in contrast to these other FGIDs, subjects with symptoms of chronic constipation were found to be at increased risk of poorer survival. Further investigation is required to determine the cause of this observed association.

Entities:  

Mesh:

Year:  2010        PMID: 20160713      PMCID: PMC2887253          DOI: 10.1038/ajg.2010.40

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  52 in total

Review 1.  Systematic review on the management of irritable bowel syndrome in North America.

Authors:  Lawrence J Brandt; David Bjorkman; M Brian Fennerty; G Richard Locke; Kevin Olden; Walter Peterson; Eamonn Quigley; Philip Schoenfeld; Marvin Schuster; Nicholas Talley
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

2.  Familial association in adults with functional gastrointestinal disorders.

Authors:  G R Locke; A R Zinsmeister; N J Talley; S L Fett; L J Melton
Journal:  Mayo Clin Proc       Date:  2000-09       Impact factor: 7.616

3.  Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact.

Authors:  R S Sandler; W F Stewart; J N Liberman; J A Ricci; N L Zorich
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 4.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

Authors:  William E Whitehead; Olafur Palsson; Kenneth R Jones
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

5.  Health-related quality of life among persons with irritable bowel syndrome: a systematic review.

Authors:  H B El-Serag; K Olden; D Bjorkman
Journal:  Aliment Pharmacol Ther       Date:  2002-06       Impact factor: 8.171

6.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

7.  The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST).

Authors:  A Haycox; T Einarson; A Eggleston
Journal:  Scand J Gastroenterol Suppl       Date:  1999

8.  Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.

Authors:  Ron L Akehurst; John E Brazier; Nigel Mathers; Caroline O'Keefe; Eva Kaltenthaler; Anne Morgan; Maria Platts; Stephen J Walters
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Gastrointestinal tract symptoms and self-reported abuse: a population-based study.

Authors:  N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

Review 10.  The epidemiology of irritable bowel syndrome in North America: a systematic review.

Authors:  Yuri A Saito; Philip Schoenfeld; G Richard Locke
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  60 in total

1.  Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Stephen J Vanner; William G Paterson; Ron J Bridges
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

2.  Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.

Authors:  Ruchit Sood; Alexander C Ford
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

3.  Offshore training in navy personnel is associated with uninvestigated dyspepsia.

Authors:  Fan Li; Gang Sun; Yun-Sheng Yang; Li-Hong Cui; Li-Hua Peng; Xu Guo; Wei-Feng Wang; Bin Yan; Lanjing Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

4.  Bowel movement frequency, oxidative stress and disease prevention.

Authors:  Alphons J M Vermorken; Emmanuel Andrès; Yali Cui
Journal:  Mol Clin Oncol       Date:  2016-08-10

5.  Effects of Birth Cohorts on the Irritable Bowel Syndrome Support Early-Life Risk Factors.

Authors:  Neil R Brummond; G Richard Locke; Rok Seon Choung; Joseph Y Chang; Cathy D Schleck; Alan R Zinsmeister; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2015-02-14       Impact factor: 3.199

6.  "First Do No Harm": Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia.

Authors:  Thomas M Goodsall; Nicholas J Talley
Journal:  Dig Dis Sci       Date:  2017-11       Impact factor: 3.199

7.  Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome.

Authors:  Andrea Shin; Sarah Ballou; Michael Camilleri; Huiping Xu; Anthony Lembo
Journal:  Clin Gastroenterol Hepatol       Date:  2019-09-20       Impact factor: 11.382

8.  Five-year follow-up of 263 cases of functional bowel disorder.

Authors:  Yu-Rong Tang; Ping Wang; Rui Yin; Jian-Xin Ge; Guo-Pin Wang; Lin Lin
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

9.  The current prevalence of irritable bowel syndrome in Asia.

Authors:  Full-Young Chang; Ching-Liang Lu; Tseng-Shing Chen
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

10.  Is Rome III Criteria for Irritable Bowel Syndrome More Useful Than Rome II Criteria in Korea?: Author's Reply.

Authors:  Dong Won Park; Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-07-27       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.